PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Empirically used in clinical practice; preclinical studies show antidepressant-like responses in animal models [PMID:37265761].
Ameliorated 3-hour memory loss induced by sleep deprivation in a Drosophila model [PMID:31057652].
Leaf extracts (AJLE) induced browning of 3T3L1 white adipocytes and inhibited adipogenesis in vitro [PMID:37511251].
Various julibrosides (triterpenoid saponins) demonstrated cytotoxic activity against human cancer cell lines including HeLa, HepG2, and A549 in vitro [PMID:9051910, 28764915, 33770687, 16504508].
Clinical trials indicated herbal preparations containing A. julibrissin extracts may shorten healing time and reduce inflammation compared to conventional treatments [PMID:36839954].
Evidence summary
PubMed sources
- 1.PMID: 40869099 (2025) — Pharmacological Spectrum of Substances Derived from Albizia julibrissin Durazz. · International journal of molecular sciences
- 2.PMID: 39770479 (2024) — (-)-Syringaresinol Exerts an Antidepressant-like Activity in Mice by Noncompetitive Inhibition of the Serotonin Transporter. · Pharmaceuticals (Basel, Switzerland)
- 3.PMID: 37265761 (2023) — Molecular basis and mechanism of action of Albizia julibrissin in depression treatment and clinical application of its formulae. · Chinese herbal medicines
- 4.PMID: 33453433 (2021) — Five TPSs are responsible for volatile terpenoid biosynthesis in Albizia julibrissin. · Journal of plant physiology
- 5.PMID: 34940902 (2021)